Celiac Disease Drugs Market Competitive Landscape 2020, Global Analysis by Size, Growth Rate, Key Trends, drug type, diagnosis, Treatment and Regional Forecast

Celiac disease is an autoimmune disorder that cause damage and inflammation to the small intestine and mostly found in people who are hereditarily inclined towards gluten. Some of the symptoms of celiac disease are gastrointestinal malfunctions such as diarrhea, abdominal distention, loss of appetite, and among kids’ failure to grow normally and also sometimes loss of lymphocytes. Coeliac disease is triggered when the body reacts to gluten, generally found in wheat and in other grains such as barley and rye.

Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/168

100% gluten-free diet is the only existing treatment for celiac disease

According to the National Foundation for Celiac Awareness (NFCA), celiac disease affects both men and women of all age groups and races. It is estimated that around 83% of all local Americans who have celiac disease are untreated or misdiagnosed with other bowel disorders. People with untreated celiac disease incur additional average medical costs of US$ 3,964 as compared to healthy individuals. Of all the people diagnosed with celiac disease, 5-22% have an immediate family member who was diagnosed with celiac disease. There are no specific drugs to treat celiac diseases. The total number of individuals diagnosed in the U.K. with celiac disease has increased fourfold between 1990 and 2011, from 5.2 per 100,000 to 19.1 per 100,000. This inadvertently creates a highly conducive environment for the growth of the celiac disease drugs market, once such a drug is commercialized in the market.

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/168

Bowel biopsy the only available method to confirm celiac disease: current scenario of the market

The celiac disease drugs are still undergoing clinical trials as it is difficult to identify celiac disease in the primary stages, because the symptoms are deceptively similar to those of other bowel disorders. Various subtle and selective blood tests such as anti-tissue transglutaminase antibodies are used to screen the disease. If the test results are positive, then the individual is asked to undergo a small bowel biopsy to confirm the disease, as there is no specific or defined treatment. Nevertheless, extensive R&D activities are currently underway are expected to pave way for more effective and advanced diagnostic options and innovative drugs, which is expected to position the global celiac disease drugs market on a high growth trajectory.

Celiac Disease Drugs Market Outlook: A sea of opportunity beckons

Regional segmentation by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. According to the University of Chicago Medicine, Celiac Disease Center, approximately 1% of healthy average Americans are affected by celiac disease. In 2007, 3 million individuals were affected with Celiac Disease and 97% of people are undiagnosed and untreated. Around 3 million people were suffering from diabetes type1, out of which 6% (180,000) also had celiac disease; around 610,000 unexplained infertility cases were reported, out of which 6% also suffered from celiac disease. The prevalence of the celiac disease in the U.S. in healthy people is 1 in 133 and is estimated at 1 in 56 in people with related symptoms. People with first degree and second-degree relatives suffering from celiac disease are 1 in 22 and 1 in 39, respectively. This creates highly lucrative growth opportunities for players in the global celiac disease drugs market, post clinical trial approval. The Asia Pacific is likely to show high growth rates in the year’s post-drug approval in the global celiac disease drugs industry, with China and India being the highest revenue contributors. On the other side, strict regulatory frameworks for drug approval are expected to hamper the market growth.

Major players

Key players operating the market include Alvine Pharmaceuticals, Inc., Alba Therapeutics Corporation, ImmusanT, and the Institute for Protein Design. All the above-mentioned companies have their celiac disease drugs in clinical trial phase I and II.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/celiac-disease-drugs-market-168

Key Developments

• Key players in the market are focused on the approval and launch of novel drugs intended for the treatment of celiac disease. For instance, in August 2019, ActoBio Therapeutics, Inc., a wholly-owned subsidiary of Intrexon Corporation, announced that the U.S. Food and Drug Administration (FDA) granted an Investigational New Drug (IND) application for AG017, an orally-delivered drug for the treatment of celiac disease.
• Moreover, in August 2019, Innovate Biopharmaceuticals, Inc., a clinical-stage biotechnology company based in the U.S., announced first patient enrollment in its Phase III clinical trial, CeD LA 3001 for Larazotide acetate, a drug candidate for the treatment of celiac disease.
• Major institutes and universities are focused on R&D activities related to celiac disease. For instance, in August 2019, researchers from the Massachusetts General Hospital and The Walter and Eliza Hall Institute, Australia, found that gluten-specific CD4+ T cells are rapidly reactivated by antigen -exposure likely causing celiac disease-associated gastrointestinal symptoms. The development is expected to offer a diagnostic blood test for celiac disease.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837